CTKB
Cytek Biosciences, Inc.4.7000
+0.0600+1.29%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
600.96MP/E (TTM)
-Basic EPS (TTM)
-0.11Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Q2 revenue dips 2%, Evo launches
Cytek Biosciences reported Q2 2025 revenue of $45.6 million, down 2% from last year amid EMEA and APAC softness, yet recurring revenue surged 16% to comprise 32% of trailing 12-month total. The company added 146 instruments, boosting its installed base to 3,295 units, and launched the enhanced Cytek Aurora Evo system for faster throughput and better resolution. It narrowed full-year revenue guidance to $196–$205 million. Cash reserves dipped slightly to $262 million despite a $4.5 million share repurchase.
10-Q
Q2 FY2025 results
Cytek Biosciences posted Q2 revenue of $45.6M, down 2% y/y but up 5% q/q (derived), with product sales slipping 9% y/y to $31.4M amid softer U.S. academic and EMEA biopharma demand, while service revenue climbed 18% y/y to $14.2M on a growing installed base. Gross margin held at 52%, down from 55% y/y, as higher service costs offset lower product volumes. Operating loss narrowed to $10.6M from $8.5M y/y, thanks to 12% lower R&D spend; net loss improved to $5.6M or $(0.04) per diluted share from $10.4M or $(0.08), reconciling to 127M weighted shares. Cash and equivalents stood at $75.5M with $186.6M in marketable securities, long-term debt at $0.8M, and $15.1M used in share repurchases; free cash flow not disclosed in the 10-Q. Ongoing patent litigation with Beckman Coulter poses a key risk, potentially disrupting product sales.
8-K
Annual meeting elects director, ratifies auditor
Cytek Biosciences held its 2025 annual meeting on June 18, with 81.4% of shares participating. Richard Chin secured election as Class I director with strong support, while Deborah Neff faced heavy withholding and fell short. Say-on-pay for executives won advisory approval from 76 million votes, and Deloitte's auditor role was ratified overwhelmingly. Shareholder dissent on Neff highlights board scrutiny.
A
Agilent Technologies, Inc.
139.19-1.41
AVTR
Avantor, Inc.
11.20-0.08
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
CERS
Cerus Corporation
2.16+0.15
CTSO
Cytosorbents Corporation
0.64+0.01
LAB
Standard BioTools Inc.
1.49-0.02
MXCT
MaxCyte, Inc.
1.47-0.02
PACB
Pacific Biosciences of Californ
2.02-0.10
SSMXF
Sysmex Corp.
9.33+0.00